Recruiting

Phase 2

Enfortumab Vedotin & PembrolizumabEnfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Sponsor:

Emory University

Code:

NCT05756569

Conditions

Bladder Squamous Cell Carcinoma

Locally Advanced Bladder Carcinoma

Malignant Renal Pelvis Neoplasm

Malignant Ureter Neoplasm

Malignant Urethral Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Enfortumab Vedotin

Magnetic Resonance Imaging

Pembrolizumab

Study Details

Brief summary:

This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving enfortumab vedotin and pembrolizumab may kill more tumor cells in patients with locally advanced or metastatic bladder cancer of variant histology.

Conditions

Bladder Squamous Cell Carcinoma

Locally Advanced Bladder Carcinoma

Malignant Renal Pelvis Neoplasm

Malignant Ureter Neoplasm

Malignant Urethral Neoplasm

Study ID

NCT05756569

Start date

Sep 26, 2023

Status verified date

Jul, 2026

Completion date

Dec 16, 2027

Anticipated

Primary completion date

Dec 16, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Male or Female
Age >= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
Metastatic disease or unresectable locally advanced disease
Histologically documented variant histology (nested, microcytic, micropapillary, lymphoepithelioma-like, plasmacytoid, giant cell, poorly differentiated, lipid-rich, clear cell, sarcomatoid) bladder cancer and non-urothelial bladder cancer of epithelial origin including squamous cell carcinoma and adenocarcinoma (urachal and non-urachal). Variant histology tumors and non-urothelial tumors of ureter, urethra, urachus, or renal pelvis are included. Patients with mixed cell type are eligible if the predominant histology (over 50%) is variant or non-urothelial. All histological classifications will follow the 2016 WHO Classifications.
Untreated or having received any number of lines of prior therapy
Tumor tissue samples must be available for submission prior to initiation of study treatment. If not, agree to undergo biopsy
Patients must have measurable disease as defined by RECIST criteria 1.1 as at least one lesion that can be accurately measured in at least one dimension (longest diameter of >= 10 mm for non-nodal lesions or short axis of >= 15 mm for nodal lesions) on CT scan, MRI
Patients must have adequate organ and marrow function, within 28 days of cycle 1 day 1, at the discretion of the investigator
The effects of study drugs on the developing human fetus are unknown. For this reason, female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy
FCBP and men treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Additionally, FCBP and male subjects should use effective contraception for 6 months after the last dose. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Male subjects must not donate sperm and female subjects must not donate ova from screening to 6 months after the last dose
A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer >= 4 weeks before the start of study therapy
Life expectancy > 12 weeks as determined by the Investigator
Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions
Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation

Exclusion Criteria:

The neuroendocrine histology (small cell and large cell carcinomas) and non-epithelial bladder tumors (e.g. bladder sarcoma, carcinosarcoma, paraganglioma, melanoma, primary lymphoma, and lymphoepithelioma-like carcinoma) are excluded.
Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier \[i.e. ongoing clinically significant toxicity (grade 2 or higher with the exception of alopecia) associated with prior treatment\]
Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in study
Patients with ongoing sensory or motor neuropathy grade >= 2
Prior treatment or enrollment in a study with EV or PD1/PD-L1 immune checkpoint inhibitor (including maintenance therapy)
Known uncontrolled diabetes mellitus with glycated hemoglobin (HbA1c) >= 8% or HbA1c 7% to < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained
Active central nervous system (CNS) metastases
Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for localized prostate cancer, definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past 24 months
Currently receiving systemic antimicrobial treatment for active infection or high dose steroids (> 10mg of prednisone or equivalent)
A FCBP who has a positive urine pregnancy test at baseline or within 72 hours prior to receiving first study dose. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Breastfeeding females
History of active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs), known hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive), known active hepatitis C virus (defined as HCV ribonucleic acid \[mRNA\] \[qualitative\] is detected) or tuberculosis
History of active keratitis or corneal ulcerations
History of allogenic tissue/solid organ transplant
Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias within 6 months prior to first dose of EV/pembrolizumab
Other uncontrolled current illness including, but not limited to, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment (enfortumab vedotin, pembrolizumab)

Patients receive enfortumab vedotin IV and pembrolizumab IV on study. Patients also undergo CT scan or MRI, and collection of blood throughout the trial.

Interventions

Biospecimen Collection

Undergo collection of blood

Computed Tomography

Undergo CT

Enfortumab Vedotin

Given IV

Magnetic Resonance Imaging

Undergo MRI

Pembrolizumab

Given IV

Questionnaire Administration

Ancillary studies

Primary outcome measure

Overall response rate [ Time Frame: Up to 2 years ]

Central Contacts and Locations

Central contacts

Jacqueline Brown, MD

404-778-1900 jacqueline.theresa.brown@emory.edu

Locations

Grady Health System

Recruiting

Atlanta, Georgia, United States, 30303

Contacts

Wilena Session

404-778-4005 wsessio@emory.edu

Principal Investigator:

Jacqueline Brown, MD

Emory University Hospital Midtown

Recruiting

Atlanta, Georgia, United States, 30308

Contacts

Wilena Session

404-778-4005 wsessio@emory.edu

Principal Investigator:

Jacqueline Brown, MD

Emory University Hospital/Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Wilena Session

404-778-4005 wsessio@emory.edu

Principal Investigator:

Jacqueline Brown, MD

Emory Saint Joseph's Hospital

Recruiting

Atlanta, Georgia, United States, 30342

Contacts

Wilena Session

404-778-4005 wsessio@emory.edu

Principal Investigator:

Jacqueline Brown, MD

More Information

Sponsor

Emory University

Last update posted

Jul 29, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Emory University on 2026-07-29.